Drug intelligence / Profile preview

JNJ-27390467

Development stage: Preclinical
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Oral (preclinical/animal Studies)

Overview

JNJ-27390467 is a potent, nonpeptide small molecule inhibitor of human mast cell tryptase. It was developed as an experimental agent for the treatment of diseases involving mast cell activation and degranulation, such as asthma and other immune or respiratory disorders. The compound is a spirocyclic piperidine amide derivative that selectively inhibits tryptase activity, with demonstrated oral efficacy in animal models of airway inflammation[1][2][3].

Other names: JNJ-27390467 free baseJNJ27390467 free baseJNJ 27390467 free baseCHEMBL255590CHEMBL-255590CHEMBL 255590DB06962DB-06962DB 06962B700BD3K5YB-700BD3K5YB 700BD3K5Y1025795-11-2

Targets

TPSB2 (Mast Cell Tryptase)

Beyond the preview

Go deeper on JNJ-27390467.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-27390467.

Explore the full profile